Jam

Innospec will release its Q4 and full-year 2025 earnings on February 17, 2026. A conference call with leadership will follow on February 18, 2026, to discuss segment performance, profitability, cash flow, and ESG initiatives. Registration is required for the call, and a webcast will be available.

LightPath Technologies will participate in the 28th Annual Needham Growth Conference on January 15, 2026. The company, a leader in advanced optics and imaging for defense and commercial sectors, will conduct one-on-one investor meetings. Management plans to discuss their strategic initiatives, unique chalcogenide glass technology, and reinforced financial position, highlighting their commitment to growth and shareholder value in the evolving optics and photonics market.

Aura Minerals achieved record quarterly production in Q4 2025, exceeding guidance and ending the year strong. The company reported 82,067 gold equivalent ounces (GEO), a 23% increase year-over-year. Full-year 2025 production reached 280,414 GEO. Key drivers included the Borborema project’s ramp-up and the acquisition of Mineração Serra Grande. While Aranzazu saw a decline at current prices, other mines like Almas and Apoena contributed positively. Aura Minerals is focused on growth through new projects, exploration, and acquisitions, projecting over 600,000 GEO annually in the future.

AB InBev has secured an exclusive UK partnership with Live Nation, becoming the sole beer and cider provider for their festivals and venues. This deal will feature brands like Budweiser and Stella Artois at major events including Reading & Leeds and across Academy Music Group venues, aiming to connect with millions of music fans. Both companies highlight the synergy between music and beverages, promising enhanced fan experiences through activations and curated selections.

CelLBxHealth plc has appointed Peter Collins as its new CEO and added three Non-Executive Directors to its board. This strategic realignment aims to bolster growth and governance, leveraging the Parsortix® platform for circulating tumor cell analysis. The new leadership brings diverse expertise to drive product sales, enhance lab services, and develop new tests, while investors will be watching for tangible strategic advancements.

Mattel introduces its first autistic Barbie doll, developed with the Autistic Self Advocacy Network (ASAN). This inclusive Fashionistas doll features articulated limbs, adjusted eye gaze, sensory-supportive accessories like a fidget spinner and headphones, and comfortable attire. The collaboration aims to provide authentic representation, foster understanding, and ensure autistic children see themselves reflected in play. The doll’s launch is accompanied by partnerships with autistic advocates and donations to pediatric hospitals.

The global PC market saw strong growth in 2025, with shipments up 9.2% to 279.5 million units. Notebooks and desktops both experienced significant increases. However, rising memory and storage costs, alongside supply chain constraints, are driving price hikes and tempering forecasts for 2026. Vendors are prioritizing higher-margin products to navigate these challenges, while a healthy demand environment persists.

Faraday Future is targeting 2026 with a dual focus on electric vehicles and “Embodied AI” (EAI) robotics, planning to launch its robotics products in February 2026. Driven by rising labor costs and its AI-centric DNA, the company sees robotics as a complementary growth engine with lighter investment needs. Faraday Future also aims to expand its FX Super One EV pre-orders and market presence across ten U.S. states. Key 2026 goals include achieving positive gross margins on robots, accelerating EAI market entry, expanding EV reach, and securing capital, all while navigating pending regulatory certifications and a conditional $10 million investment from AIxC.

Teva Pharmaceutical Industries will unveil its “Pivot to Growth” strategy and financial outlook through 2030 at the J.P. Morgan Healthcare Conference. The company aims to transform into a leading biopharmaceutical entity, leveraging its generics business and innovative pipeline.

For 2025, Teva projects revenues of $16.8–$17.0 billion, with substantial free cash flow and EBITDA targets. Looking ahead, it aims for mid-single-digit revenue CAGR by 2030 and over $3.5 billion in free cash flow, alongside reduced net leverage and an investment-grade credit rating. While near-term revenue may be flat, the strategy emphasizes pipeline advancement and financial discipline.

Allegiant Travel Company is acquiring Sun Country Airlines for approximately $1.5 billion, aiming to create a dominant U.S. leisure travel powerhouse. This merger will combine complementary networks, fleets, and customer offerings, expanding service to over 175 cities and 18 international destinations. The deal emphasizes operational agility, diversified revenue streams, and enhanced loyalty programs. The combined entity will operate under the Allegiant name, headquartered in Las Vegas, with integration expected to yield significant financial synergies.